Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Gracell Biotechnologies Inc ADR (GRCL)

Gracell Biotechnologies Inc ADR (GRCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 744,950
  • Shares Outstanding, K 72,678
  • Annual Sales, $ 0 K
  • Annual Income, $ -88,080 K
  • 60-Month Beta -0.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.35
Trade GRCL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.05
  • Most Recent Earnings $-0.10 on 11/13/23
  • Latest Earnings Date 03/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.21
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.25
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.97 +2.86%
on 01/22/24
10.44 -1.77%
on 02/09/24
+0.26 (+2.60%)
since 01/19/24
3-Month
3.80 +169.73%
on 11/28/23
10.44 -1.77%
on 02/09/24
+5.36 (+109.61%)
since 11/21/23
52-Week
1.40 +632.14%
on 04/26/23
10.44 -1.77%
on 02/09/24
+8.16 (+390.43%)
since 02/21/23

Most Recent Stories

More News
Why Shares of Gracell Biotechnologies Are Rising Monday

The company said it is receiving financing of up to $150 million dollars from private investors.

GRCL : 10.25 (+0.05%)
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

GRCL : 10.25 (+0.05%)
Why Shares of Gracell Biotechnologies Jumped Tuesday

Gracell climbed higher for a second consecutive day.

GRCL : 10.25 (+0.05%)
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

GRCL : 10.25 (+0.05%)
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

GRCL : 10.25 (+0.05%)
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

GRCL : 10.25 (+0.05%)
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

GRCL : 10.25 (+0.05%)
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

GRCL : 10.25 (+0.05%)
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

GRCL : 10.25 (+0.05%)
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

/PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and...

GRCL : 10.25 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company. It involved in discovering and developing breakthrough cell therapies to address unmet medical needs in the treatment of cancer. Gracell Biotechnologies Inc. is based in SUZHOU, China.

See More

Key Turning Points

3rd Resistance Point 10.41
2nd Resistance Point 10.34
1st Resistance Point 10.30
Last Price 10.25
1st Support Level 10.19
2nd Support Level 10.12
3rd Support Level 10.08

See More

52-Week High 10.44
Last Price 10.25
Fibonacci 61.8% 6.98
Fibonacci 50% 5.92
Fibonacci 38.2% 4.85
52-Week Low 1.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar